124 related articles for article (PubMed ID: 37549060)
1. PACT: a pipeline for analysis of circulating tumor DNA.
Webster J; Dang HX; Chauhan PS; Feng W; Shiang A; Harris PK; Pachynski RK; Chaudhuri AA; Maher CA
Bioinformatics; 2023 Aug; 39(8):. PubMed ID: 37549060
[TBL] [Abstract][Full Text] [Related]
2. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
3. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
4. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
5. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients.
Valle-Inclan JE; Stangl C; de Jong AC; van Dessel LF; van Roosmalen MJ; Helmijr JCA; Renkens I; Janssen R; de Blank S; de Witte CJ; Martens JWM; Jansen MPHM; Lolkema MP; Kloosterman WP
Genome Med; 2021 May; 13(1):86. PubMed ID: 34006333
[TBL] [Abstract][Full Text] [Related]
7. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
9. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA.
Gawroński AR; Lin YY; McConeghy B; LeBihan S; Asghari H; Koçkan C; Orabi B; Adra N; Pili R; Collins CC; Sahinalp SC; Hach F
Nucleic Acids Res; 2019 Apr; 47(7):e38. PubMed ID: 30759232
[TBL] [Abstract][Full Text] [Related]
10. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
11. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with
Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D
Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654
[TBL] [Abstract][Full Text] [Related]
13. TNER: a novel background error suppression method for mutation detection in circulating tumor DNA.
Deng S; Lira M; Huang D; Wang K; Valdez C; Kinong J; Rejto PA; Bienkowska J; Hardwick J; Xie T
BMC Bioinformatics; 2018 Oct; 19(1):387. PubMed ID: 30342468
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis.
Saha S; Araf Y; Promon SK
J Egypt Natl Canc Inst; 2022 Feb; 34(1):8. PubMed ID: 35187602
[TBL] [Abstract][Full Text] [Related]
15. Aperture: alignment-free detection of structural variations and viral integrations in circulating tumor DNA.
Liu H; Yin H; Li G; Li J; Wang X
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34368852
[TBL] [Abstract][Full Text] [Related]
16. Circulating cell-free tumor DNA analysis in pediatric cancers.
Andersson D; Fagman H; Dalin MG; Ståhlberg A
Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
[TBL] [Abstract][Full Text] [Related]
17. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients.
Guo W; Jin L; Liang J; Lin G; Zheng J; Zhou D; Zhan S; Sun H; Jiang X
Clin Chim Acta; 2022 Sep; 534():81-92. PubMed ID: 35810802
[TBL] [Abstract][Full Text] [Related]
18. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
19. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
